MTX+PBO (n=55) | MTX+ETN (n=55) | ||
---|---|---|---|
Site | Leeds | n=46 | n=48 |
Huddersfield | n=4 | n=3 | |
Harrogate | n=2 | n=4 | |
York | n=3 | n=0 | |
Age (years) | Mean (SD), range | 48.38 (13.34), 26–79 | 47.91 (13.58), 18–80 |
Female | % (n) | 72.7% (40/55) | 80.0% (44/55) |
Symptom duration (months) | Median (IQR), range | 8 (6 to 11), 3–18 | 6 (4 to9), 1–21 |
DAS44-CRP | Mean (SD) | 2.95 (0.91) | 2.94 (0.92) |
DAS28-CRP | Mean (SD) | 4.17 (1.10) | 4.10 (1.14) |
RF-positive | % (n) | 55.6% (30/54) | 56.4% (31/55) |
ACPA-positive | % (n) | 80.8% (42/52) | 72.2% (39/54) |
SE positive (1 copy) | % (n) | 63.5% (33/52) | 43.4% (23/53) |
SE positive (2 copies) | % (n) | 21.2% (11/52) | 35.8% (19/53) |
HAQ-DI | Mean (SD) | 1.00 (0.43), n=53 | 1.01 (0.47), n=53 |
SF-36 MCS | Mean (SD) | 42.45 (12.23), n=49 | 46.82 (10.19), n=51 |
SF-36 PCS | Mean (SD) | 35.51 (7.90), n=49 | 36.00 (8.04), n=51 |
EQ-5D-3L | Mean (SD) | 0.569 (0.252), n=53 | 0.578 (0.245), n=52 |
Median (1st Q, 3rd Q) | 0.587 (0.516 to 0.760) | 0.620 (0.516 to 0.760) | |
ERO | Mean (SD) | 1.36 (2.95), n=49 | 1.10 (1.84), n=40 |
Median (IQR) | 0.0 (0.0 to 1.5) | 0.0 (0.0 to 1.5) | |
JSN | Mean (SD) | 6.65 (6.03), n=49 | 5.59 (4.28), n=40 |
Median (1st Q, 3rd Q) | 4.5 (2.3 to 9.5) | 5.3 (1.8 to 9.3) | |
mTSS | Mean (SD) | 8.01 (8.06), n=49 | 6.69 (5.04), n=40 |
Median (IQR | 5.5 (2.8 to 11.3) | 5.5 (2.8 to 10.0) |
ACPA, anticitrullinated protein antibody; DAS44-CRP, disease activity score based on RAI and SJC44; EQ-5D-3L, Euroqol 5-dimensional 3-level response standardised health outcome tool; ERO, erosion; ESR, erythrocyte sedimentation rate; ETN, etanercept; HAQ-DI, Rasch-transformed health assessment questionnaire disability index score; JSN, joint space narrowing; mTSS, van der Heijde modified total Sharpe score; MTX, methotrexate; Q, quartile; RAI, Ritchie articular index; RAQoL, Rasch-transformed rheumatoid arthritis quality of life score; RF, rheumatoid factor; SE, shared epitope.